Unacylated ghrelin and AZP531 suppress the 3D growth of breast cancers
Au, C. C.; Furness, J. B.; Britt, K.; Oshchepkova, S.; Ladumor, H.; Soo, K. Y.; Callaghan, B.; Gerard, C.; Inghirami, G.; Mittal, V.; Wang, Y.; Huang, X.-Y.; Spector, J. A.; Andreopoulou, E.; Zumbo, P.; Betel, D.; Dow, L. E.; Brown, K. A.
Show abstract
Breast cancer is the most common type of cancer in women and notwithstanding important therapeutic advances, it remains the second leading cause of cancer-related death in the US. Despite extensive research relating to the hormone ghrelin, responsible for the stimulation of growth hormone release and appetite, little is known of the effects of its unacylated form, especially in cancer. One major area of research relates to its reported effects to increase insulin sensitivity in diabetics, this being the basis for the development of unacylated ghrelin analog, AZP531 or livoletide, now in clinical trials for the treatment of Prader-Willi Syndrome. The mechanism of action of unacylated ghrelin is largely uncharacterized, in any system, because it does not bind to or activate the cognate ghrelin receptor, GHSR1a. The present study aimed to characterize effects of unacylated ghrelin on breast cancer cells, define its mechanism of action, and explore the therapeutic potential of unacylated ghrelin or analog AZP531. We report potent effects of unacylated ghrelin, at picomolar doses, on the growth of breast cancer cells, dependent on 3D culture and activation of Gi. Suppression of MAPK signaling by unacylated ghrelin leads to cell cycle arrest and apoptosis. AZP531 also suppresses the growth of breast cancer cells in vitro and in xenografts, and may be a novel approach for the safe and effective treatment of breast cancer.
Matching journals
The top 13 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- BET inhibition induces an anti-apoptotic adaptive response and therapeutic vulnerability to MCL1 inhibitors in breast cancer 93%
- Spontaneous aggressive ERα+ mammary tumor model is driven by Kras activation 92%
- Reciprocal epigenetic Sox2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer 91%
Similar papers in this journal
- ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer 93%
- A positive feedback loop between ZEB2 and ACSL4 regulates lipid metabolism to promote breast cancer metastasis 93%
- Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism 93%
Similar papers in this journal
- Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer 94%
- EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition 94%
- A SNAI2-PEAK1 stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting a cytokine expression profile that converges on PI3K/Akt signaling 93%
Similar papers in this journal
- WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in breast and gynecologic cancers 93%
- Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics 92%
- Zinc Alpha-2-Glycoprotein (ZAG/AZGP1) secreted by triple-negative breast cancer promotes tumor microenvironment fibrosis. 92%
Similar papers in this journal
- The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer 94%
- PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer 93%
- HIF-dependent expression of creatine kinase brain isoform (CKB) promotes breast cancer metastasis, whereas cyclocreatine therapy impairs invasion and improves the efficacy of conventional chemotherapies 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.